MARKET

ACAD

ACAD

Acadia Pharmaceuticals Inc
NASDAQ
20.80
-0.16
-0.74%
Opening 10:24 05/21 EDT
OPEN
20.64
PREV CLOSE
20.95
HIGH
20.89
LOW
20.41
VOLUME
210.15K
TURNOVER
--
52 WEEK HIGH
28.35
52 WEEK LOW
19.69
MARKET CAP
3.56B
P/E (TTM)
9.50
1D
5D
1M
3M
1Y
5Y
1D
Assessing ACADIA Pharmaceuticals (ACAD) Valuation After Pipeline Progress And Product Rollouts
Simply Wall St · 10h ago
Weekly Report: what happened at ACAD last week (0511-0515)?
Weekly Report · 3d ago
How ACADIA’s (ACAD) Solid Q1 Revenue and Pipeline Update Has Changed Its Investment Story
Simply Wall St · 4d ago
Biopharmas look to China, elsewhere for partnerships, R&D
Seeking Alpha · 6d ago
BMO Capital Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)
TipRanks · 05/11 12:05
Weekly Report: what happened at ACAD last week (0504-0508)?
Weekly Report · 05/11 09:32
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Mixed Q1 2026 Results And EU Trofinetide Setback
Simply Wall St · 05/10 22:21
Acadia Pharmaceuticals (ACAD) Margin Expansion To 34.3% Tests Bearish Growth Concerns
Simply Wall St · 05/08 22:00
More
About ACAD
Acadia Pharmaceuticals Inc.is a biopharmaceutical company. The Company is focused on innovation that makes the difference for underserved neurological and rare disease communities around the world. Its commercial portfolio includes the first and only FDA-approved treatments for Parkinson's disease psychosis and Rett syndrome. It is also developing therapeutic advancements with diverse pipelines that include mid- to late-stage programs in Alzheimer's disease psychosis and Lewy body dementia psychosis, along with earlier-stage programs that address other underserved patient needs. Its pipeline of product candidates includes Remlifanserin (formerly ACP-204), ACP-211, ACP-711, ACP-271, ACP-259, and Antisense Oligonucleotide (ASO) Program. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. DAYBUE (trofinetide) is developed for the treatment of Rett Syndrome.

Webull offers ACADIA Pharmaceuticals Inc stock information, including NASDAQ: ACAD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACAD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACAD stock methods without spending real money on the virtual paper trading platform.